Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders (PANDA)

Nycomed

Status: Completed

Conditions: Sleep Disorders; Gastroesophageal Reflux Disease; Non-Erosive Reflux Disease

Treatments: Drug: Pantoprazole

Study type: Observational

Funder types: Industry

Identifiers

NCT00830115

P2-9999-010-DE

Details and patient eligibility

About

The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease). The prevalence and intensity of the sleep disorders were evaluated by a standardized questionnaire. The study was expected to provide further data on safety and tolerability of pantoprazole.

Enrollment: 1,045 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Main inclusion criteria:

• Outpatients with erosive gastro-esophageal reflux disease (eGERD) or non-erosive reflux disease (NERD)

Main exclusion criteria:

• Criteria as defined in the respective Summary of Product Characteristics (Chapter 4.3)

Trial design

1,045 participants in 1 patient group

Pantoprazole

Description:

All patients enrolled

Treatment:

Drug: Pantoprazole